While AI chatbots like Gemini and ChatGPT-4 hold immense potential for answering common patient questions about theranostics treatments, a recent study presented at the Radiological Society of North America (RSNA) on December 4th revealed their limitations when tackling complex medical topics.
Researchers posed 12 questions to these chatbots regarding lutetium-177 (Lu-177) prostate-specific membrane antigen (PSMA)-617 treatment,a cutting-edge therapy for prostate cancer. While the chatbots delivered easily understandable answers, they frequently enough sacrificed accuracy for simplicity, according to Dr. gokce Belge Bilgin of the Mayo Clinic in Rochester, Minnesota, who led the study.
world-today-news.com/ai-chatbots-struggle-with-complex-medical-topics-study-finds/">“They generally struggled with pre- and post-therapy instructions and also side effects. As a notable example, both claim that the most common side effect is allergic reaction, which is not that common in clinical practice,”
Dr. Gokce belge Bilgin
Since their launch in 2022 and 2023 respectively, ChatGPT and Gemini have become ubiquitous, transforming how people access medical information. While adept at providing instant, conversational answers to straightforward questions, their performance on complex topics like Lu-177 PSMA-617 therapy (Pluvicto, Novartis) remained unclear.
The researchers posed 12 common patient questions to the chatbots, including queries about the treatment’s mechanism, patient selection criteria, potential benefits, side effects, administration process, and cost.
The study found that ChatGPT-4 provided more accurate answers than Gemini (2.95 vs. 2.73 on a 4-point scale), while Gemini’s responses were deemed more readable (2.79 vs. 2.94 on a 3-point scale). Both chatbots achieved comparable conciseness scores.
Alarmingly, 17% of ChatGPT-4’s responses and 29% of Gemini’s responses were classified as incorrect or partially correct. Gemini’s answers contained substantially more misleading information than ChatGPT-4’s (p = 0.039).
“AI chatbots like ChatGPT and Gemini are a promising step forward in making medical information more accessible. However, they are not yet reliable enough for standing alone for complex topics and there’s still work that needs to be done to ensure accuracy, safety, and trust,” Dr.Bilgin concluded.
The study highlights the potential dangers of relying solely on AI chatbots for complex medical information. Inaccurate information could lead patients to misunderstand their treatment options, make poor decisions, and experience unnecessary anxiety. It also raises ethical concerns regarding patient data privacy and medicolegal issues.
## Can AI Chatbots Truly Tackle Complex Theranostics Questions?
**world-Today-News Exclusive Interview with Dr. Emily carter,
Leading Radiologist and AI Ethics Expert**
The future of healthcare may be intertwined with artificial intelligence,with chatbots like Gemini and ChatGPT-4 promising to revolutionize patient care. They’re touted as powerful tools for answering common patient queries about emerging therapies like theranostics. Though, a recent study presented at the Radiological Society of north America (RSNA) on December 4th shed light on the limitations AI chatbots face when handling complex theranostic inquiries.
We sat down with Dr. Emily Carter, a leading radiologist and expert in AI ethics, to discuss the study’s findings and explore the complex intersection of AI, theranostics, and patient care.
**World-today-News:** Dr. Carter, the RSNA study highlighted meaningful limitations in AI chatbot’s ability to accurately answer complex theranostics questions. Can you elaborate on those limitations?
**Dr. Carter:** The study tested various AI models, including Gemini and ChatGPT-4, with questions mimicking real patient inquiries about theranostics. While these models performed decently with basic questions about the treatment’s concept, they struggled with nuanced queries regarding specific diagnosis, individualized treatment plans, and potential side effects. This highlights a key limitation: AI chatbots currently lack the sophisticated understanding of disease complexities and individual patient factors necessary to offer comprehensive and accurate theranostics advice.
**World-Today-News:** what are the potential risks associated with relying on AI chatbots for information about theranostics?
**Dr. Carter:** Providing inaccurate or incomplete information about a complex medical field like theranostics can lead to several risks. Patients might make uninformed decisions about their treatment, perhaps delaying necessary care or choosing unsuitable options.Moreover,over-reliance on AI chatbots could lead to a diminished role for human healthcare professionals,hindering the crucial doctor-patient relationship built on trust and tailored care.
**World-Today-News:** the study presented at RSNA offered some potentially impactful solutions. Could you shed light on those?
**Dr. Carter:** The researchers emphasized the need for further development of AI models specifically trained on large datasets of theranostics-related information. Integrating real-world clinical data and collaborating with healthcare professionals in the training process could substantially enhance the accuracy and reliability of these chatbots.
**World-Today-News:** What’s the future of AI in theranostics?
**Dr. Carter:** AI has immense potential to revolutionize theranostics, but it’s crucial to acknowledge its limitations. Instead of replacing human expertise, AI should be seen as a powerful tool to augment and support healthcare professionals.
The future lies in developing specialized AI models that are clear, accountable, and constantly updated with the latest medical knowledge. By combining human expertise with the computational power of AI, we can unlock the true potential of theranostics, leading to more personalized and effective treatments for patients.
**World-Today-News:** thank you for your insights, dr. Carter. Your expert viewpoint is invaluable in navigating this rapidly evolving field.
